SCHEMBL2070682

SCHEMBL2070682

CCOC(=O)Nc1ccc(N)cc1I

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.58
CYP2C9 P11712 3/20 0.58
CYP2C19 P33261 3/20 0.58
SMN1; SMN2 Q16637 1/20 0.56
KCNQ3 O43525 4/20 0.46
KCNQ2 O43526 4/20 0.46
KCNQ4 P56696 1/20 0.46
KCNQ5 Q9NR82 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
NLRP3 Q96P20 1/20 0.43
CYP3A4 P08684 2/20 0.43
MAPK1 P28482 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ABCB11 O95342 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069555 0.88 MEN1 (0.52) CYP1A2CYP2C9CYP2C19SMN1; SMN2MEN1
SCHEMBL404929 0.86 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19SMN1; SMN2MEN1
SCHEMBL2069644 0.84 SMN1; SMN2 (0.73) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL11451154 0.84 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL2072406 0.83 CYP1A2 (0.59) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL656064 0.83 CYP1A2 (0.59) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL11722034 0.82 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL10876647 0.81 NLRP3 (0.60) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL14637560 0.81 HDAC1 (0.60) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ3
SCHEMBL2071192 0.81 CYP1A2 (0.56) CYP1A2CYP2C9CYP2C19SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906537-B2 Substituted p-diaminobenzene derivatives H. LUNDBECK A/S (DK) 2011-03-15 US disclosed
US-20060183791-A1 Substituted p-diaminobenzene derivatives H. LUNDBECK A/S (DK) 2006-08-17 US disclosed
CN-1761464-A Substituted p-diaminobenzene derivatives LUNDBECK & CO AS H (DK) 2006-04-19 CN disclosed
EP-1613303-A1 SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES H. Lundbeck A/S (DK) 2006-01-11 EP disclosed
WO-2004082677-A1 SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES H. LUNDBECK A/S (DK) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183791-A1 Substituted p-diaminobenzene derivatives ABCB1, UGT2B7, CYP2D6 CYP1A2 20/4885CYP2C9 25/4885CYP2C19 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.